Mackenzie Financial Corp bought a new position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 543 shares of the biopharmaceutical company’s stock, valued at approximately $204,000.
Several other large investors also recently modified their holdings of REGN. Steward Partners Investment Advisory LLC boosted its position in Regeneron Pharmaceuticals by 495.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 369 shares of the biopharmaceutical company’s stock valued at $138,000 after buying an additional 307 shares during the period. Advisory Services Network LLC lifted its position in shares of Regeneron Pharmaceuticals by 147.0% in the 4th quarter. Advisory Services Network LLC now owns 447 shares of the biopharmaceutical company’s stock worth $168,000 after purchasing an additional 266 shares during the period. Vident Investment Advisory LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $200,000. AE Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $206,000. Finally, Moors & Cabot Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $217,000. 66.38% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Regeneron Pharmaceuticals stock traded down $1.25 during trading hours on Thursday, reaching $333.62. 275,159 shares of the company traded hands, compared to its average volume of 967,447. The company has a current ratio of 3.82, a quick ratio of 3.18 and a debt-to-equity ratio of 0.11. Regeneron Pharmaceuticals Inc has a one year low of $313.53 and a one year high of $543.55. The firm has a market cap of $35,955.38, a P/E ratio of 32.41, a PEG ratio of 1.05 and a beta of 1.54.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $5.23 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $4.18 by $1.05. Regeneron Pharmaceuticals had a return on equity of 28.48% and a net margin of 20.41%. The business had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.50 billion. During the same quarter in the prior year, the firm posted $3.04 EPS. The business’s quarterly revenue was up 28.9% compared to the same quarter last year. research analysts anticipate that Regeneron Pharmaceuticals Inc will post 19.2 EPS for the current year.
Several research analysts recently issued reports on REGN shares. BTIG Research reaffirmed a “buy” rating and set a $520.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, November 22nd. BMO Capital Markets set a $444.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “hold” rating in a report on Monday, November 27th. JPMorgan Chase & Co. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, November 28th. Citigroup downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $480.00 to $380.00 in a report on Friday, December 1st. Finally, TheStreet downgraded shares of Regeneron Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Thursday, November 30th. Four equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. Regeneron Pharmaceuticals has a consensus rating of “Hold” and an average price target of $449.49.
In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 1,000 shares of the firm’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $325.60, for a total value of $325,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Joseph L. Goldstein sold 2,000 shares of the firm’s stock in a transaction on Monday, March 19th. The stock was sold at an average price of $350.02, for a total value of $700,040.00. Following the completion of the sale, the director now directly owns 14,000 shares of the company’s stock, valued at $4,900,280. The disclosure for this sale can be found here. Insiders have sold a total of 5,000 shares of company stock worth $1,705,640 in the last quarter. Insiders own 10.80% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.